Glonghui, March 28 | Lepu Bio-B (02157.HK) announced the results for the year ended December 31, 2023. The company's revenue increased from approximately RMB 16 million in the previous year to approximately RMB 225 million, an increase of approximately 1347.2%. The company's losses to its parent fell sharply by about 96.8%, from approximately RMB 689 million in the previous year to approximately RMB 122 million in the same year. During the reporting period, the company recorded breakthrough revenue and made significant progress in the product pipeline and business operations. The Group's BD revenue and subsequent technical service revenue was approximately RMB 124 million, and the commercial revenue of Puyouheng (putrizumab injection) was approximately RMB 101 million. The company will focus on deepening marketing and commercialization in 2024, and actively expand the company's market footprint and product awareness in China. The company will take further action to promote market access for Puyouheng (prutelizumab injection), continue to accelerate market penetration at all levels, and further expand its market share. The company believes that efforts to strengthen market expansion will translate into better market access, higher market share, and overall sales of the company's commercialized products and brands, thus laying a solid market and channel foundation for the future commercialization of the company's ADC product pipeline. On the international side, the company will step up its efforts to expand into the global market. Since the company's ADC platform has been recognized by multinational companies, the company anticipates that the company's other ADC products will have greater opportunities for business development. The company will continue to contact many overseas companies to seek potential business development cooperation opportunities.